The ESMO congress, scheduled for October 23–27, 2026, will feature Leads Biolabs' latest clinical findings across multiple indications, including extrapulmonary neuroendocrine carcinoma and biliary tract cancer. Beyond the two selected Proffered Papers, four additional studies will be showcased as posters. The company also confirmed it has been granted Late-Breaking Abstract status, with the full data set expected to be finalized in September.

Dr. Charles Cai, Chief Medical Officer at Leads Biolabs, described the ESMO recognition as a milestone in the company's efforts to establish its drug candidates as global standards. The firm's lead asset, Opamtistomig, is currently positioned as an IO 2.0 pan-tumor therapy, having already secured Breakthrough Therapy Designation in China and Fast Track status from the U.S. FDA for neuroendocrine carcinoma. Simultaneously, the company is preparing for an oral presentation at the World Conference on Lung Cancer in September, where it will present data on the drug's efficacy in first-line non-small cell lung cancer.

Leads Biolabs continues to leverage its proprietary LeadsBody and X-Body platforms to develop bispecific antibodies. With 14 candidates now in its pipeline, the company is shifting focus toward advancing registrational trials and expanding its commercial footprint, aiming to provide durable clinical responses for patients with limited treatment options.